# KOOKMIN BIO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kookmin-bio

- Industry: Biotechnology
- Headquarters: Jeonju, South Korea
- Website: www.kmbio.co.kr
- Total disclosed funding: $4M
- Latest round: Series B (Nov 20, 2024)
- Investors on record: 6

## About

Based in South Korea, KOOKMIN BIO develops innovative microbiome-based health solutions aimed at enhancing consumer well-being through advanced food and pharmaceutical products.KOOKMIN BIO, founded in 2019 in Jeonju, South Korea, focuses on creating microbiome health products. The company has executed 5 deals and recently raised KRW 3.4 billion in Series B funding on November 20, 2024, from investors including Chung-Ang University KAIC and Industrial Bank of Korea. The founder's specific history is not publicly documented.Kookmin Bio specializes in the development of microbiome-based health solutions aimed at enhancing consumer well-being through innovative food and pharmaceutical products. Their core offerings include postbiotics boosters, soy-based convenience foods, and health supplements designed to support muscle recovery and weight management. These products utilize proprietary fermentation technologies that combine beneficial lactic acid bacteria with domestic soybean powder to improve nutrient absorption and promote overall health. Targeting health-conscious consumers, athletes, and middle-aged individuals, Kookmin Bio's products are primarily marketed in South Korea and seek to expand into international markets, addressing global health trends and consumer needs for effective dietary supplements and functional foods.Kookmin Bio operates on a business model that encompasses both direct-to-consumer sales and partnerships with retailers to distribute its innovative health products. The company engages in B2B transactions with health retailers and wellness providers, facilitating a range of product offerings tailored to meet the needs of various client demographics. Their flagship products, such as the fermented soy milk and postbiotic boosters, are positioned within the health and wellness market, providing consumers with targeted solutions for muscle enhancement and weight management. Kookmin Bio's revenue streams are generated through the sales of these products, which leverage their advanced proprietary technologies to ensure efficacy and safety, aligning with consumer demand for reliable health solutions.In November 2024, KOOKMIN BIO raised KRW 3.4 billion in Series B funding, with plans to utilize the capital to expedite clinical research and human testing for microbiome-regulating biopharmaceuticals. The company is also targeting expansion into international markets, although specific regions and timelines have not been detailed. Upcoming product launches are anticipated as part of their strategy to enhance their market presence.

## Funding rounds

- Series B, Nov 20, 2024, $2.4M — Industrial Bank of Korea, New Paradigm Investment, K-Ground Ventures, Chung-Ang University KAIC
- Series A, May 20, 2022, $1.6M — New Paradigm Investment, Chung-Ang University KAIC, KMU Holdings
- Seed, Feb 1, 2022 — Korea Tech Incubator for Startup, New Paradigm Investment

## Investors

- Korea Tech Incubator for Startup — Seed
- New Paradigm Investment (https://capitalatlas.ai/funds/new-paradigm-investment) — Seed, Series A, Series B
- Chung-Ang University KAIC — Series A, Series B
- KMU Holdings — Series A
- Industrial Bank of Korea — Series B
- K-Ground Ventures (https://capitalatlas.ai/funds/k-ground-ventures) — Series B